Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

For over a decade, Humira has been the highest-grossing drug in the world, bringing in some $21 billion for manufacturer AbbVie in 2021. Humira is a versatile drug used to treat multiple ...

AbbVie reported solid Q1 2025 results, raising full-year guidance and showing strong growth in Skyrizi and Rinvoq offsetting Humira's decline. Despite entering the obesity market, AbbVie's ...

AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the loss of exclusivity (“LOE”) and biosimilar erosion.

AbbVie (NYSE:ABBV) continued gains for seven straight sessions, as the stock closed 1.3% higher at $189.90 on Friday. The North Chicago-based pharma giant gained about 1% in the preceding six ...

“AbbVie reported solid Q1 2025 results, raising full-year guidance and showing strong growth in Skyrizi and Rinvoq offsetting Humira's decline,” pointed out Seeking Alpha analyst Daniel ...

Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms ...

Humira (adalimumab) has potential interactions with other medications and certain vaccines. For example, Humira can interact with prednisone, warfarin, and live vaccines for measles, mumps, and ...

With this approval, Yuflyma is now fully interchangeable with the reference product, Humira (adalimumab), across all marketed dosage forms and strengths. Yuflyma is a high-concentration ...

AbbVie’s fourth quarter earnings exceeded expectations on both revenue and EPS, driven by continued growth in its immunology and neuroscience franchises, alongside stabilizing trends in Humira ...